Peritoneal Dialysis Is the Best Modality for Old, Frail People

Abstract

An ageing population in the UK has seen an increased prevalence of chronic kidney disease (CKD), with a higher proportion of old, frail people requiring kidney replacement therapy. This article aims to explore why peritoneal dialysis (PD) may be the optimal dialysis modality for older people, considering factors such as frailty and cognitive impairment. PD offers considerable benefits over haemodialysis, including improved quality of life, benefits to cognition and higher treatment satisfaction. Assisted PD supports the maintenance of treatment for those with physical or cognitive impairments and helps to alleviate caregiver burden. Despite this, challenges such as treatment burden and peritonitis should be thoroughly considered. Overall, PD aligns well with the priorities of older people, emphasising quality of life and autonomy over survival. However, there needs to be improved funding and access to assisted PD programmes going forward to ensure PD is a viable treatment option.

Graphical abstract

Keywords

peritoneal dialysis / frailty / cognitive impairment / quality of life / assisted peritoneal dialysis

1. Introduction

Over 11 million people in the UK are aged 65 years and older, making up almost 19% of the total population [1]. As chronic kidney disease (CKD) becomes more common with increasing age, its prevalence is increasing with higher numbers of older people subsequently requiring kidney replacement therapy (KRT) [2]. There is also an increasingly frail population [3]. Whilst clinically distinct from ageing, frailty is common in those with CKD. Discussions about KRT should therefore be tailored to consider the potential challenges of ageing and frailty experienced by older people.

KRT encompasses haemodialysis (HD), peritoneal dialysis (PD) and kidney transplantation, although older people are less likely to undergo transplantation due to issues of both short- and long-term complications related to age and/or frailty [4]. Many older patients subsequently default to HD [2], which may not be the optimal dialysis modality for the old, frail person. Alternatively, PD offers a home-based therapy which may be more suitable, with possible benefits as shown in Fig. 1. This review will explore the reasons why PD may be the best treatment for frail, elderly individuals (Fig. 2), taking into account patient characteristics that should form the basis of shared decision-making.

2. Frailty

Frailty is defined as a state of increased vulnerability alongside declining physiological function [5]. Its presence has an adverse effect on clinical outcomes for older people with CKD [6] and higher rates of mortality in dialysis patients [7]. Different models for frailty have been hypothesised. One of the most widely used is the Fried frailty phenotype which encompasses weight loss, fatigue, weakness, poor mobility and low physical activity [8]. These characteristics present a complex array of challenges and increased symptom burden for those with end-stage kidney disease (ESKD), including falls, cognitive impairment, hospitalisation and premature death [9]. Integration of elderly care physicians and use of the Comprehensive Geriatric Assessment has allowed for clearer identification and management of these frailty syndromes in the outpatient setting [10].

There is an increasing prevalence of frailty in both those with CKD and on dialysis; one study found that 82% of older people with CKD stage 5 fitted the criteria for frailty [11]. The impact of frailty was demonstrated in the Frail and Elderly Person on Dialysis (FEPOD) study. They showed that frailty was the main predictor in outcomes measured between groups of older people on assisted PD versus HD, with higher treatment satisfaction in those on assisted PD [12].

For those on HD, frailty can increase the risk of hospitalisation (odds ratio (OR), 2.47; 95% confidence interval (CI), 1.52–4.03, p 0.001), vascular access events (hazard ratio (HR), 1.72; 95% CI, 1.50–1.97, p 0.001), depression (OR, 4.31; 95% CI, 1.83–10.18, p = 0.001) and falls (pooled incidence rate ratio, 2.42; 95% CI, 1.39–4.21, p = 0.002). Frailty further correlates with a worse quality of life in HD patients (OR, 0.955; 95% CI, 0.925–0.987, p 0.01) [13]. People on HD additionally experience prolonged time to recovery post-dialysis, which can be more marked in the frail, elderly population [14].

Frailty also affects outcomes for people on PD [15], but this is comparatively understudied in the elderly. Positive treatment characteristics of PD include daily delivery of treatment with shorter recovery time, no requirement for vascular access and fewer hospital visits. These factors may help to mitigate the impact of frailty in older people, and a thorough assessment of frailty should be central to all decision-making on KRT.

3. Cognitive Impairment

Cognitive impairment (CI) is highly prevalent amongst the old, frail population, and to a greater degree in those with advanced CKD [16]. The implications of this are significant. There are impacts on executive function and attention [16], as well as increased mortality [17]. More widely, CI can lead directly to an increased incidence of depression, which may in turn worsen cognition and associated functioning [18]. Therefore, the presence of CI should be assessed with onward referral to the memory clinic if undiagnosed dementia is suspected.

CI is accelerated on HD via HD-induced circulatory ischaemia, white matter insults and increased rates of cerebrovascular accidents. One study demonstrated a reduction in global cerebral blood flow of 10% during HD in a cohort of 12 patients aged over 65 years (p = 0.03), suggesting that it was this repeated insult which contributed to progressive CI in those on HD [19]. Additional research explored the longer-term consequences of HD by using magnetic resonance imaging (MRI). The images demonstrated cerebral atrophy (p 0.05) and white matter changes (p = 0.02) over a 12-month period in a cohort of 97 HD patients [20]. Further, intradialytic hypotension (IDH) may be experienced by old, frail people on HD, and can further contribute to CI [21] as well as falls [22]. Repeated episodes of IDH were shown to be directly correlated to loss of white matter (p = 0.003) and hippocampal volume (p = 0.001) on MRI imaging in a cohort of 68 HD patients, even when these episodes were asymptomatic [23].

The risk of stroke is also higher in HD patients. A large cohort study of almost 21,000 patients found that stroke rates began to increase up to 90 days before starting HD and peaked within the first 30 days post-HD start (p 0.0001). At 12 months the stroke rate remained almost double that compared to pre-HD rates [24]. Cerebrovascular events are well documented to have adverse effects on cognition over time, alongside consequences for mobility and independence. In addition, cardiovascular risk factors are highly prevalent amongst the HD population, with ESKD considered an independent risk factor [25], further contributing to stroke risk. Anaemia management in CKD with erythropoiesis stimulating agents (ESA) may carry an additional stroke risk which should be considered concurrently [26].

Conversely, PD has less of an impact on cognitive health as it avoids large fluid shifts and IDH. A large retrospective study of over 120,000 patients supported this by demonstrating a lower incidence of dementia in a PD cohort when compared with people on HD (PD vs HD: 3.9% (95% CI [3.3%, 4.4%]) vs 7.3% (95% CI [7.1%, 7.4%])) [27]. A subsequent direct comparison of cognitive function in 41 HD patients and 25 PD patients found that Montreal Cognitive Assessment (MoCA) scores declined more rapidly in the HD cohort over the two-year study period (coefficient = –0.12; 95% CI, –0.233 to –0.007, p = 0.037). The study also noted that cognition declined faster in those on any form of dialysis (HD or PD) when compared to people with CKD not on dialysis (coefficient = –0.03; 95% CI, –0.056 to –0.004, p = 0.025) [28]. This could suggest that severe CI may be seen as a relative contraindication to any form of KRT.

However, CI in PD patients can lead to frequent hospital admissions and increased peritonitis rates [29]. This highlights the complex interplay of the frailty syndromes and the challenges experienced by clinicians. CI should not just be viewed as an eventuality of ageing. Multi-disciplinary team (MDT) assessment of elderly patients with CI should evaluate the individual’s baseline cognition and level of function in order to determine which dialysis modality is best. Assessment by a geriatrician and/or referral to a memory clinic may also be sought. A preference for PD, if there is pre-existing dementia, can be appropriate, but it would likely be delivered via an assisted programme to ensure optimal care.

4. Quality of Life and Patient Choice

Multiple studies have shown that there may be no survival advantage to any dialysis modality for frail, elderly individuals [30, 31, 32], making survival a secondary consideration in discussions of KRT. Instead, quality of life is more likely to be prioritized [33] and can be influenced by frailty and cognitive impairment as already discussed. What contributes to a person’s quality of life should be explored to determine the goals of the individual and their expectations of treatment.

A recent study conducted a choice experiment which found that older people aged >65 years had other preferences besides survival when deciding on options for KRT. This included location and frequency of care, treatment burden and preservation of capability [34]. 327 participants made a trade-off between these factors when they were presented with surveys focused on KRT decision-making, with only 55% being categorised as ‘survival prioritizers’. They also noted that there was no prediction from sociodemographic data as to what individuals would prioritize. It should further be acknowledged that the priorities of old, frail people may not be the same as those perceived by their treating team [35]. This reinforces the importance of thorough discussion of options for KRT in the advanced kidney care clinic, enabling the clinician to manage the person according to their own values.

Quality of life was examined in the Broadening Options for Long-term Dialysis in the Elderly (BOLDE) study, which compared cohorts of patients aged 65 years and over on HD versus PD [36]. Despite no difference in quality of life outcome measures, perception of illness intrusion (p = 0.006) and feelings of depression (p = 0.015) were less in the group on PD. Whilst treatment burden can be significant in home-based therapy, this study suggested that people found treatment with PD less invasive.

Despite some older people prioritizing a reduction in symptom burden in end-stage kidney disease (ESKD), it is important to acknowledge that PD often does not result in a total resolution of symptoms. Oedema can be improved; however, fatigue can persist despite starting PD [37]. Limitations of treatment should be clearly communicated.

PD can also be tailored to adapt to the specific needs of the individual via an incremental regimen. This step-wise approach to PD enables a gradual increase in their prescription over time as dictated primarily by symptoms, thus allowing for preservation of their residual kidney function [38]. This enables greater flexibility with the dialysis prescription whereby dialysis days can be altered to accommodate hospital appointments and social events; things that older people may prioritize more readily.

Further PD actively encourages people to be involved in delivery of their own care through performing daily exchanges or attaching themselves to the overnight cycler machine used in automated peritoneal dialysis (APD). This contributes to an increased sense of autonomy whilst remaining in a familiar home environment in close contact with family and friends [39]. Older people on PD may also act as carers for spouses or children, and so being at home is integral for them to continue in their role. These lifestyle advantages of PD can mean less frequent hospital visits and an enhanced overall well-being for patients.

5. Assisted Peritoneal Dialysis

Ageing and frailty may present problems with cognition and dexterity, which may in turn impact a person’s ability to carry out their own PD. In such scenarios, assisted PD is a valuable resource which can be utilised to enable ongoing dialysis at home. Assisted PD can include help from registered nurses, healthcare assistants and dialysis technicians as well as trained carers. People may initially perform independent continuous ambulatory peritoneal dialysis (CAPD) or APD before gaining assistance, or commence directly onto assisted PD. A switch from independent PD to assisted PD is often due to intercurrent events or a change in social circumstances, and can be preferable compared to transferring to HD. This flexibility makes PD a viable option for many old, frail people; some of whom may have foregone dialysis altogether had this option not been available. It may also be used as a bridge to self-care PD in the old, frail person where longer training time and support from community teams is required [40].

Assisted PD can also be provided by friends and family. These caregivers should therefore be involved in shared decision-making when discussing KRT. It is also necessary to recognise carer burnout, and assisted PD can be implemented to provide temporary respite if needed. Opposingly, older people may have reduced social support but still wish to pursue a home-based therapy. The benefits and flexibility of assisted PD and the role of the family are illustrated in the case discussion in Table 1.

6. Models of Assisted PD

Funding and healthcare policies are significant barriers to the provision of assisted PD. Wide variations are seen nationally and internationally—across Europe, 40% of units providing PD were found to have no access to a formal assisted service [41]. Formal assisted programmes differ within the UK also. Assistants can be employed directly by National Health Service (NHS) trusts or organised by a partnership between commercial dialysis providers and healthcare agencies. France was one of the first countries to roll out a government-funded assisted PD programme where registered nurses are trained to undertake the PD, as well as providing catheter care and monitoring of blood pressure and fluid status. This facility has since been extended to nursing homes, providing a true holistic service [42]. Table 2 (Ref. [12, 40, 42, 43]) summarises the differing models for delivering assisted PD globally.

Assisted programmes have allowed an expansion in accessibility to PD where it may not have been a viable treatment option previously. It also presents a balance of autonomy and appropriate support to ensure the goals and wishes of the individual are not compromised. The use of assisted PD has also been demonstrated to reduce the need for modality switch to HD in the elderly [44] and increase incident PD numbers in the elderly population [45]. Palliative use of assisted PD is another option for those people who elect to continue PD but do not have the capability themselves [46]. As such, early consideration and ongoing review of the need for assistance should be encouraged when reviewing old, frail people. However, this can only be appropriately done if the local programmes are funded and staffed appropriately.

7. Economic Considerations

The ageing population has dictated focused cost analysis of KRT in order to drive further improvements in service design and accessibility of treatment for patients. In 2023, dialysis costs in the UK totalled £1.05 billion, with an additional £225 million spent on transport to haemodialysis [47]. The cost of CAPD and APD is less than in-centre HD, and without transport costs [48]. Assisted PD has also been demonstrated to be highly cost-effective compared to HD, even when providing this service to those in long-term care facilities [49]. Financial incentives to increase numbers on PD have been employed in other countries [50], but this is less relevant in the UK given the publicly funded structure of the NHS. The rising economic implications of CKD, ESKD and KRT could therefore be alleviated by an increase in the proportion of the elderly on PD.

8. Challenges of PD and Consideration of Other Treatments

Potential challenges of PD should also be considered, and are summarised in Table 3. Peritonitis is a significant complication and its risk remains controversial. One study showed similar peritonitis rates between age groups, with an incidence of peritonitis of 1 episode per 23.6 patient-months in those aged \ge75 years compared to 1 episode per 23 patient-months in a younger cohort [51]. In comparison, Wu et al. [52] demonstrated higher peritonitis rates amongst those aged \ge65 years compared with younger patients (0.203 vs 0.145 episodes/patient-year, p 0.05). This was supported by a subsequent meta-analysis of four studies showing increased peritonitis risk in patients over the age of 65 (relative risk (RR), 1.56; 95% CI, 1.18–2.07, p = 0.002) [53]. The use of an assisted service has also been considered in the context of PD peritonitis. A study of 334 elderly patients suggested assistant-assisted treatment inferred an increased peritonitis risk (HR, 2.64; 95% CI, 1.23–5.64, p = 0.012) [52]. However, a large study from the French Language Peritoneal Dialysis Registry demonstrated a lower peritonitis risk in those on assisted programmes [54]. The conflicting findings from these studies are perhaps explained by rates of comorbidity and frailty of older populations in different countries and varying cohort sizes. Improved adherence to exit site care and subsequent reduction in exit site infection has also been associated with a decreased risk of peritonitis [55]. Differences in technique and service design could further account for the variability seen. Hospitalisation subsequent to peritonitis is also significant; the Peritoneal Dialysis Outcomes and Practice Patterns Study showed hospital admission occurred in more than two-thirds of peritonitis episodes [56]. The burden of repeated hospital admissions, the impact of an episode of PD peritonitis and the trajectory of recovery in the setting of other comorbidities should be considered for all elderly patients who opt for treatment with PD.

Another consideration is the repetitive nature of PD. Patients often carry out 2–3 exchanges per day which can contribute to a significant treatment burden. In turn, this may negatively impact on perceived quality of life, alongside carer burnout if family assistance is heavily relied upon. To mitigate this, incremental regimens and preservation of residual kidney function allow for dialysis flexibility with scheduled days off as needed [57]. Assisted PD further helps to reduce dependency on relatives.

In-centre HD may also be a good option for older people who physically cannot do their own PD for reasons of dexterity or mobility, or if they are limited by visual or cognitive impairment. There also may be positive impacts of HD which a frail, elderly person may find encouraging. Loneliness in the elderly is a growing problem and the benefit of regular social contact within a dialysis unit should not be overlooked, particularly for those people who live alone [58]. Further, modality change to HD may be seen for PD patients with infection, catheter dysfunction and ultrafiltration failure [59].

However, HD presents a different set of problems, including vascular access issues [60], rigid weekly schedules [61] and extra time spent on hospital transport [62]. Weighing up the benefits and burdens of each modality is therefore important to ensure an individualised treatment plan.

9. Consideration of Maximal Conservative Management

Maximal conservative management, whereby medications are used in place of dialysis treatments to manage symptoms of ESKD, should also be considered where appropriate. Elderly patients starting dialysis can experience only marginal improvements in life expectancy with less time spent at home [63]. When considering this alongside frailty and other comorbidities, PD may still be too burdensome for some. In this scenario, early involvement of the palliative care teams is paramount to ensuring patient-centred care with clear decisions around advanced care planning and resuscitation.

10. Conclusion

Decisions around KRT in the old, frail population can be complex. However, where appropriate, PD offers a home-based treatment that can be flexible to suit the needs of the individual. The goals of treatment of the older person are less likely to be centred on survival, and may instead focus on quality of life, treatment satisfaction and maintenance of independence. These aims are well aligned with what PD offers as a dialysis modality, and are also supported by numerous large cohort studies. The impact of cognition and frailty should be closely examined and discussed with both the person and the wider MDT to ensure individualised care. When challenges are identified that may hinder the delivery of PD in elderly patients, assisted PD should be considered to help to maintain their independence and continue with their dialysis.

Looking to the future, the role of assisted PD programmes is likely to become more important with an ageing population and the increasing prevalence of frailty. The economic benefits of PD should also be evaluated as the pressure on HD units continues to rise. As such, there is a need for improved funding and restructuring of services to enable the development and provision of assisted programmes across the UK. Sharing of models of care between renal units to enhance learning should be encouraged. Further, external funding options from private dialysis companies should be considered for the provision of staff and training to enable this treatment option to be offered more readily to those who require it.

Key Points

\bullet Frailty is a key determinant when making decisions about KRT and treatment outcomes, and the Comprehensive Geriatric Assessment should be increasingly used to evaluate this.

\bullet Peritoneal dialysis is a home-based treatment with less impact on cognition compared to haemodialysis, thus a good treatment for older people and those who have pre-existing cognitive impairment.

\bullet Quality of life measures may be more important than survival in the old, frail population.

\bullet Assisted PD is a good option to explore for old, frail people but needs adequate funding and staffing resources.

Availability of Data and Materials

All the data of this study are included in this article.

References

[1] Office for National Statistics. Profile of the older population living in England and Wales in 2021 and changes since 2011. 2023. Available at: https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/ageing/articles/profileoftheolderpopulationlivinginenglandandwalesin2021andchangessince2011/2023-04-03 (Accessed: 11 November 2024).

[2] UK Renal Registry. UK Renal Registry 26th Annual Report. 2024. Available at: https://www.ukkidney.org/audit-research/annual-report/26th-annual-report-data-31122022 (Accessed: 6 November 2024).

[3] Walsh B, Fogg C, Harris S, Roderick P, de Lusignan S, England T, et al. Frailty transitions and prevalence in an ageing population: longitudinal analysis of primary care data from an open cohort of adults aged 50 and over in England, 2006-2017. Age and Ageing. 2023; 52: afad058. https://doi.org/10.1093/ageing/afad058.

[4] Haugen CE, Chu NM, Ying H, Warsame F, Holscher CM, Desai NM, et al. Frailty and Access to Kidney Transplantation. Clinical Journal of the American Society of Nephrology. 2019; 14: 576–582. https://doi.org/10.2215/CJN.12921118.

[5] Hoogendijk EO, Afilalo J, Ensrud KE, Kowal P, Onder G, Fried LP. Frailty: implications for clinical practice and public health. Lancet. 2019; 394: 1365–1375. https://doi.org/10.1016/S0140-6736(19)31786-6.

[6] Kallenberg MH, Kleinveld HA, Dekker FW, van Munster BC, Rabelink TJ, van Buren M, et al. Functional and Cognitive Impairment, Frailty, and Adverse Health Outcomes in Older Patients Reaching ESRD-A Systematic Review. Clinical Journal of the American Society of Nephrology. 2016; 11: 1624–1639. https://doi.org/10.2215/CJN.13611215.

[7] Zhang Q, Ma Y, Lin F, Zhao J, Xiong J. Frailty and mortality among patients with chronic kidney disease and end-stage renal disease: a systematic review and meta-analysis. International Urology and Nephrology. 2020; 52: 363–370. https://doi.org/10.1007/s11255-019-02369-x.

[8] Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al. Frailty in older adults: evidence for a phenotype. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences. 2001; 56: M146–M157. https://doi.org/10.1093/gerona/56.3.m146.

[9] Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K. Frailty in elderly people. Lancet. 2013; 381: 752–762. https://doi.org/10.1016/S0140-6736(12)62167-9.

[10] Voorend CGN, Berkhout-Byrne NC, van Bodegom-Vos L, Diepenbroek A, Franssen CFM, Joosten H, et al. Geriatric Assessment in CKD Care: An Implementation Study. Kidney Medicine. 2024; 6: 100809. https://doi.org/10.1016/j.xkme.2024.100809.

[11] Joseph J, Vellaisamy M, Subramanian T, Fernando E, Kaliaperumal T, Nd S, et al. Frailty in Patients With Chronic Kidney Disease Stage Five. Cureus. 2023; 15: e43787. https://doi.org/10.7759/cureus.43787.

[12] Iyasere OU, Brown EA, Johansson L, Huson L, Smee J, Maxwell AP, et al. Quality of Life and Physical Function in Older Patients on Dialysis: A Comparison of Assisted Peritoneal Dialysis with Hemodialysis. Clinical Journal of the American Society of Nephrology. 2016; 11: 423–430. https://doi.org/10.2215/CJN.01050115.

[13] Cheng M, He M, Ning L, Gan H, Liu H, Liu Q, et al. Association between frailty and adverse outcomes in patients undergoing maintenance hemodialysis: a systematic review and meta-analysis. Renal Failure. 2024; 46: 2367716. https://doi.org/10.1080/0886022X.2024.2367716.

[14] Fitzpatrick J, Sozio SM, Jaar BG, Estrella MM, Segev DL, Shafi T, et al. Frailty, Age, and Postdialysis Recovery Time in a Population New to Hemodialysis. Kidney360. 2021; 2: 1455–1462. https://doi.org/10.34067/KID.0001052021.

[15] Abraham C, Collier J, Wu HH, Martin J, Hurst H, Poulikakos D, et al. 2023. Impact of frailty status on clinical outcomes in patients receiving peritoneal dialysis. Translational Medicine of Aging. 2023; 7: 128–132. https://doi.org/10.1016/j.tma.2023.11.002.

[16] Zhang J, Wu L, Wang P, Pan Y, Dong X, Jia L, et al. Prevalence of cognitive impairment and its predictors among chronic kidney disease patients: A systematic review and meta-analysis. PLoS ONE. 2024; 19: e0304762. https://doi.org/10.1371/journal.pone.0304762.

[17] Angermann S, Schier J, Baumann M, Steubl D, Hauser C, Lorenz G, et al. Cognitive Impairment is Associated with Mortality in Hemodialysis Patients. Journal of Alzheimer’s Disease. 2018; 66: 1529–1537. https://doi.org/10.3233/JAD-180767.

[18] Agganis BT, Weiner DE, Giang LM, Scott T, Tighiouart H, Griffith JL, et al. Depression and cognitive function in maintenance hemodialysis patients. American Journal of Kidney Diseases. 2010; 56: 704–712. https://doi.org/10.1053/j.ajkd.2010.04.018.

[19] Polinder-Bos HA, García DV, Kuipers J, Elting JWJ, Aries MJH, Krijnen WP, et al. Hemodialysis Induces an Acute Decline in Cerebral Blood Flow in Elderly Patients. Journal of the American Society of Nephrology. 2018; 29: 1317–1325. https://doi.org/10.1681/ASN.2017101088.

[20] Findlay MD, Dawson J, Dickie DA, Forbes KP, McGlynn D, Quinn T, et al. Investigating the Relationship between Cerebral Blood Flow and Cognitive Function in Hemodialysis Patients. Journal of the American Society of Nephrology. 2019; 30: 147–158. https://doi.org/10.1681/ASN.2018050462.

[21] Assimon MM, Wang L, Flythe JE. Cumulative Exposure to Frequent Intradialytic Hypotension Associates With New-Onset Dementia Among Elderly Hemodialysis Patients. Kidney International Reports. 2019; 4: 603–606. https://doi.org/10.1016/j.ekir.2019.01.001.

[22] Li L, Xu W, Fang Y, Jiang Q, Zhou Y, Chen Y, et al. Construction and validation of a fall risk prediction model in elderly maintenance hemodialysis patients: a multicenter prospective cohort study. Renal Failure. 2025; 47: 2455524. https://doi.org/10.1080/0886022X.2025.2455524.

[23] Cedeño S, Desco M, Aleman Y, Macías N, Fernández-Pena A, Vega A, et al. Intradialytic hypotension and relationship with cognitive function and brain morphometry. Clinical Kidney Journal. 2021; 14: 1156–1164. https://doi.org/10.1093/ckj/sfaa070.

[24] Murray AM, Seliger S, Lakshminarayan K, Herzog CA, Solid CA. Incidence of stroke before and after dialysis initiation in older patients. Journal of the American Society of Nephrology. 2013; 24: 1166–1173. https://doi.org/10.1681/ASN.2012080841.

[25] Cozzolino M, Mangano M, Stucchi A, Ciceri P, Conte F, Galassi A. Cardiovascular disease in dialysis patients. Nephrology, Dialysis, Transplantation. 2018; 33: iii28–iii34. https://doi.org/10.1093/ndt/gfy174.

[26] Drüeke TB. Lessons from clinical trials with erythropoiesis-stimulating agents (ESAs). Renal Replacement Therapy. 2018; 4: 46. https://doi.org/10.1186/s41100-018-0187-2.

[27] Wolfgram DF, Szabo A, Murray AM, Whittle J. Risk of dementia in peritoneal dialysis patients compared with hemodialysis patients. Peritoneal Dialysis International. 2015; 35: 189–198. https://doi.org/10.3747/pdi.2014.00213.

[28] Iyasere O, Okai D, Brown E. Cognitive function and advanced kidney disease: longitudinal trends and impact on decision-making. Clinical Kidney Journal. 2017; 10: 89–94. https://doi.org/10.1093/ckj/sfw128.

[29] Aiumtrakul N, Thongprayoon C, Yingchoncharoen P, Wannaphut C, Wathanavasin W, Suppadungsuk S, et al. Addressing cognitive impairment in peritoneal dialysis: a systematic review and meta-analysis of prevalence, risk factors, and outcomes. Clinical Kidney Journal. 2024; 17: sfae312. https://doi.org/10.1093/ckj/sfae312.

[30] Harris SAC, Lamping DL, Brown EA, Constantinovici N, North Thames Dialysis Study (NTDS) Group. Clinical outcomes and quality of life in elderly patients on peritoneal dialysis versus hemodialysis. Peritoneal Dialysis International. 2002; 22: 463–470.

[31] Hussain JA, Mooney A, Russon L. Comparison of survival analysis and palliative care involvement in patients aged over 70 years choosing conservative management or renal replacement therapy in advanced chronic kidney disease. Palliative Medicine. 2013; 27: 829–839. https://doi.org/10.1177/0269216313484380.

[32] Verberne WR, Geers ABMT, Jellema WT, Vincent HH, van Delden JJM, Bos WJW. Comparative Survival among Older Adults with Advanced Kidney Disease Managed Conservatively Versus with Dialysis. Clinical Journal of the American Society of Nephrology. 2016; 11: 633–640. https://doi.org/10.2215/CJN.07510715.

[33] Hall RK, Cary MP, Jr, Washington TR, Colón-Emeric CS. Quality of life in older adults receiving hemodialysis: a qualitative study. Quality of Life Research. 2020; 29: 655–663. https://doi.org/10.1007/s11136-019-02349-9.

[34] Hole B, Coast J, Caskey FJ, Selman LE, Rooshenas L, Kimpton G, et al. A choice experiment of older patients’ preferences for kidney failure treatments. Kidney International. 2025; 107: 130–142. https://doi.org/10.1016/j.kint.2024.08.032.

[35] Ramer SJ, McCall NN, Robinson-Cohen C, Siew ED, Salat H, Bian A, et al. Health Outcome Priorities of Older Adults with Advanced CKD and Concordance with Their Nephrology Providers’ Perceptions. Journal of the American Society of Nephrology. 2018; 29: 2870–2878. https://doi.org/10.1681/ASN.2018060657.

[36] Brown EA, Johansson L, Farrington K, Gallagher H, Sensky T, Gordon F, et al. Broadening Options for Long-term Dialysis in the Elderly (BOLDE): differences in quality of life on peritoneal dialysis compared to haemodialysis for older patients. Nephrology, Dialysis, Transplantation. 2010; 25: 3755–3763. https://doi.org/10.1093/ndt/gfq212.

[37] Figueiredo AE, Goodlad C, Clemenger M, Haddoub SS, McGrory J, Pryde K, et al. Evaluation of physical symptoms in patients on peritoneal dialysis. International Journal of Nephrology. 2012; 2012: 305424. https://doi.org/10.1155/2012/305424.

[38] Alrowiyti IM, Bargman J. A Review of Residual Kidney Function in Peritoneal Dialysis Patients. Indian Journal of Nephrology. 2023; 33: 239–246. https://doi.org/10.4103/ijn.ijn_242_23.

[39] Milan Manani S, Virzì GM, Morisi N, Marturano D, Tantillo I, Giuliani A, et al. Ongoing Peritoneal Dialysis Training at Home Allows for the Improvement of Patients’ Empowerment: A Single Center Experience. Journal of Clinical Medicine. 2024; 13: 411. https://doi.org/10.3390/jcm13020411.

[40] Oliver MJ, Abra G, Béchade C, Brown EA, Sanchez-Escuredo A, Johnson DW, et al. Assisted peritoneal dialysis: Position paper for the ISPD. Peritoneal Dialysis International. 2024; 44: 160–170. https://doi.org/10.1177/08968608241246447.

[41] van Eck van der Sluijs A, van Jaarsveld BC, Allen J, Altabas K, Béchade C, Bonenkamp AA, et al. Assisted peritoneal dialysis across Europe: Practice variation and factors associated with availability. Peritoneal Dialysis International. 2021; 41: 533–541. https://doi.org/10.1177/08968608211049882.

[42] Béchade C, Lobbedez T, Ivarsen P, Povlsen JV. Assisted Peritoneal Dialysis for Older People with End-Stage Renal Disease: The French and Danish Experience. Peritoneal Dialysis International. 2015; 35: 663–666. https://doi.org/10.3747/pdi.2014.00344.

[43] Brown EA, Finkelstein FO, Iyasere OU, Kliger AS. Peritoneal or hemodialysis for the frail elderly patient, the choice of 2 evils? Kidney International. 2017; 91: 294–303. https://doi.org/10.1016/j.kint.2016.08.026.

[44] Lanot A, Bechade C, Boyer A, Ficheux M, Lobbedez T. Assisted peritoneal dialysis and transfer to haemodialysis: a cause-specific analysis with data from the RDPLF. Nephrology, Dialysis, Transplantation. 2021; 36: 330–339. https://doi.org/10.1093/ndt/gfaa289.

[45] Boyer A, Solis-Trapala I, Tabinor M, Davies SJ, Lambie M. Impact of the implementation of an assisted peritoneal dialysis service on peritoneal dialysis initiation. Nephrology, Dialysis, Transplantation. 2020; 35: 1595–1601. https://doi.org/10.1093/ndt/gfz287.

[46] Grubbs V, Moss AH, Cohen LM, Fischer MJ, Germain MJ, Jassal SV, et al. A palliative approach to dialysis care: a patient-centered transition to the end of life. Clinical Journal of the American Society of Nephrology. 2014; 9: 2203–2209. https://doi.org/10.2215/CJN.00650114.

[47] Kidney Research UK. 2023. Kidney disease: A UK public health emergency. 2023. Available at: https://www.kidneyresearchuk.org/wp-content/uploads/2023/06/Economics-of-Kidney-Disease-full-report_accessible.pdf (Accessed: 18 March 2025).

[48] Roberts G, Holmes J, Williams G, Chess J, Hartfiel N, Charles JM, et al. Current costs of dialysis modalities: A comprehensive analysis within the United Kingdom. Peritoneal Dialysis International. 2022; 42: 578–584. https://doi.org/10.1177/08968608211061126.

[49] Wong SN, Turnbull L, Saunders S, Er L, Bevilacqua MU, Levin A, et al. Evaluation and outcomes of a 5-year assisted peritoneal dialysis program. Peritoneal Dialysis International. 2024; 44: 177–184. https://doi.org/10.1177/08968608221149546.

[50] Manns B, Agar JWM, Biyani M, Blake PG, Cass A, Culleton B, et al. Can economic incentives increase the use of home dialysis? Nephrology, Dialysis, Transplantation. 2019; 34: 731–741. https://doi.org/10.1093/ndt/gfy223.

[51] Taveras AE, Bekui AM, Gorban-Brennan N, Raducu R, Finkelstein FO. Peritoneal dialysis in patients 75 years of age and older–a 22-year experience. Advances in Peritoneal Dialysis. Conference on Peritoneal Dialysis. 2012; 28: 84–88.

[52] Wu H, Ye H, Huang R, Yi C, Wu J, Yu X, et al. Incidence and risk factors of peritoneal dialysis-related peritonitis in elderly patients: A retrospective clinical study. Peritoneal Dialysis International. 2020; 40: 26–33. https://doi.org/10.1177/0896860819879868.

[53] Jiang C, Zheng Q. Outcomes of peritoneal dialysis in elderly vs non-elderly patients: A systemic review and meta-analysis. PLoS ONE. 2022; 17: e0263534. https://doi.org/10.1371/journal.pone.0263534.

[54] Duquennoy S, Béchade C, Verger C, Ficheux M, Ryckelynck JP, Lobbedez T. Is Peritonitis Risk Increased in Elderly Patients on Peritoneal Dialysis? Report from the French Language Peritoneal Dialysis Registry (RDPLF). Peritoneal Dialysis International. 2016; 36: 291–296. https://doi.org/10.3747/pdi.2014.00154.

[55] Soetendorp H, Grupper A, Hazan E, Wasserman A, Schwartz D, Kliuk-Ben Bassat O. Reduction of peritoneal dialysis associated infections using a novel exit-site care practice. Peritoneal Dialysis International. 2025; 45: 113–120. https://doi.org/10.1177/08968608241270296.

[56] Perl J, Fuller DS, Bieber BA, Boudville N, Kanjanabuch T, Ito Y, et al. Peritoneal Dialysis-Related Infection Rates and Outcomes: Results From the Peritoneal Dialysis Outcomes and Practice Patterns Study (PDOPPS). American Journal of Kidney Diseases. 2020; 76: 42–53. https://doi.org/10.1053/j.ajkd.2019.09.016.

[57] Cheetham MS, Cho Y, Krishnasamy R, Jain AK, Boudville N, Johnson DW, et al. Incremental Versus Standard (Full-Dose) Peritoneal Dialysis. Kidney International Reports. 2022; 7: 165–176. https://doi.org/10.1016/j.ekir.2021.11.019.

[58] Moreels T, Van de Velde D, Van Duyse S, Vanden Wyngaert K, Leune T, Van Biesen W, et al. The impact of in-centre haemodialysis treatment on the everyday life of older adults with end-stage kidney disease: a qualitative study. Clinical Kidney Journal. 2023; 16: 1674–1683. https://doi.org/10.1093/ckj/sfad104.

[59] Piarulli P, Vizzardi V, Alberici F, Riva H, Aramini M, Regusci L, et al. Peritoneal dialysis discontinuation: to the root of the problem. Journal of Nephrology. 2023; 36: 1763–1776. https://doi.org/10.1007/s40620-023-01759-w.

[60] Torreggiani M, Bernasconi L, Colucci M, Accarino S, Pasquinucci E, Esposito V, et al. 2021. Vascular Access, Complications and Survival in Incident Hemodialysis Patients. Kidney and Dialysis. 2021; 1: 88–99. https://doi.org/10.3390/kidneydial1020013.

[61] Jones DJ, Harvey K, Harris JP, Butler LT, Vaux EC. Understanding the impact of haemodialysis on UK National Health Service patients’ well-being: A qualitative investigation. Journal of Clinical Nursing. 2018; 27: 193–204. https://doi.org/10.1111/jocn.13871.

[62] McDonald SP, Ullah S, Dansie K, Duncanson E, Gulyani A, Davies CE, et al. The Burden of Travel-Time and Distance Traveled for Hemodialysis Patients in Australian Major City Areas. Kidney International Reports. 2023; 8: 1105–1108. https://doi.org/10.1016/j.ekir.2023.02.1077.

[63] Montez-Rath ME, Thomas IC, Charu V, Odden MC, Seib CD, Arya S, et al. Effect of Starting Dialysis Versus Continuing Medical Management on Survival and Home Time in Older Adults With Kidney Failure: A Target Trial Emulation Study. Annals of Internal Medicine. 2024; 177: 1233–1243. https://doi.org/10.7326/M23-3028.